Viltolarsen Expanded Access
 Program Closed to Further Enrollment 

On August 12, 2020 the U.S. Food and Drug Administration approved Viltepso (viltolarsen) injection for patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping therapy.  The press release is available here.  Accelerated approval is based on an increase in dystrophin.  There is an ongoing study to confirm the clinical benefit of Viltepso. Prescribing information is available  on the Viltepso website www.viltepso.com

Contact Information: NS Pharma Access Solutions 833-NSSUPRT (883-677-8778)

Effective: 13 August 2020